Thymol (THY) was found to have in vitro antifungal activity against 24 fluconazole (FLC)-resistant and 12 FLC-susceptible clinical isolates of Candida albicans, standard strain ATCC 10231 and one experimentally induced FLC-resistant C. albicans S-1. In addition, synergism was observed for clinical isolates of C. albicans with combinations of THY-FLC and THY-amphotericin B (AMB) evaluated by the chequerboard microdilution method. The interaction intensity was determined by spectrophotometry for the chequerboard assay, and the nature of the interactions was assessed using two non-parametric approaches [fractional inhibitory concentration index (FICI) and DE models]. The interaction between THY-FLC or THY-AMB in FLC-resistant and -susceptible strains of C. albicans showed a high percentage of synergism by the FICI method and the DE method. The DE model gave results consistent with FICI, and no antagonistic action was observed in the strains tested.
INTRODUCTION
The dimorphic fungus Candida albicans is a commensal organism of the human oral, gastrointestinal, vaginal, cutaneous and mucosal surfaces. However, it is also an opportunistic fungal pathogen, causing candidiasis in individuals with an underlying pathological process or deficient state. Oropharyngeal candidiasis is a common initial presentation in patients with AIDS. In patients receiving broad-spectrum antibiotics or undergoing cancer chemotherapy, C. albicans can enter the bloodstream to cause serious systemic invasive disease (Pappas et al., 2009) . Over the last few decades, the occurrence of Candida infections has increased significantly, paralleling the growing numbers of immunocompromised patients. For patients, disseminated candidiasis can be a serious disease, often resulting in death (Anttila et al., 1994) .
Amphotericin B (AMB), a polyene fungicidal agent, has been the standard drug for the treatment of candidal infections for decades, but the toxicity of its conventional form and the cost of its lipid forms limit its use (Marchetti et al., 2003) . More recently, azole antifungal compounds, which have excellent efficacy-toxicity profiles, have emerged as the principal drugs used in the treatment of candidal infections in non-neutropenic patients. The most widely used drug in both the treatment and prevention of candidiasis is fluconazole (FLC), a member of the azole family of drugs, which targets the essential enzyme Erg11, lanosterol 14a-demethylase, in the ergosterol biosynthetic pathway (Vanden Bossche, 1985) . However, in recent years, prolonged use of FLC has contributed to the development of drug resistance in C. albicans and other species . One selective pressure contributing to the emergence of drug resistance is the fungistatic rather than fungicidal character of FLC action (Uppuluri et al., 2008) . Thus, new therapeutic strategies are necessary. Improvements in the efficacy of antifungal drug therapy and reductions in toxicity may be achieved by using combination therapy (Tariq et al., 1995) .
Thymol (THY) [5-methyl-2-(1-methylethyl) phenol] is an essential oil, found primarily in thyme, oregano and tangerine peel (He et al., 1997) . Studies have shown that essential oils containing THY are widely used in medicine for their antimicrobial and disinfectant properties (Didry et al., 1994; Ogaard et al., 1997; Healing & Oppenheim, 1990) , and also act as antibacterial additives in food and feed (Burt et al., 2007) . Notably, THY has been successfully used in vitro against pathogenic fungi, including Aspergillus, C. albicans and moulds (Giordani et al., 2004; Shin & Kim, 2004) .
In this study, we assessed the in vitro antifungal activity of THY against clinical isolates of C. albicans and standard Candida strains. We also observed the in vitro interaction of combinations of drugs (THY-FLC and THY-AMB) against FLC-resistant C. albicans and FLC-susceptible C. albicans using a chequerboard microdilution assay.
METHODS
Fungal strains and materials. Twenty-two clinical isolates of FLCresistant C. albicans (Quan et al., 2006) and twelve clinical isolates of FLC-susceptible C. albicans, two clinical isolates of C. albicans TW 00313 (CDR1,2 overexpression) and TW 07239 (MDR1/ERG11 overexpression) (White et al., 2002) , and one experimentally induced FLC-resistant C. albicans S-1 (Deng et al., 2006) Antifungal susceptibility testing. In order to choose the appropriate range of drug concentrations for the combination studies, the MICs of THY, FLC and AMB against C. albicans were determined by broth microdilution using twofold serial dilutions in RPMI 1640 medium, as described by the Clinical and Laboratory Standards Institute (CLSI) (formerly the National Committee for Clinical Laboratory Standards) (approved standard M27-A) for yeasts. Three rounds of experiments were performed, and the mean MIC value was calculated. The quality control strain, C. krusei ATCC 6258, and the reference strain, C. parapsilosis ATCC 90018, were included in each batch of susceptibility tests to ensure quality. The test was carried out in 96-well flat-bottomed microtitration plates according to a published report by Quan et al. (2006) . After agitation for 15 s, the plates were incubated at 35 uC without shaking, and readings were performed after 24 h incubation by both visual reading and optical density determination at 630 nm.
For the visual reading, the MICs of FLC were determined according to CLSI procedures, growth was graded on a scale from 0 to 4, as follows: 4 indicated no reduction in growth, 3 indicated a 25 % reduction of growth, 2 indicated a 50 % reduction of growth, 1 indicated a 75 % reduction of growth and 0 indicated 100 % reduction of growth (an optically clear well). For THY and AMB, the MIC was defined as the lowest concentration showing 100 % growth suppression. We chose a 100 % growth suppression level for THY based on a published study (Koşar et al., 2008) , and a report that showed that THY expressed strong fungicidal activity against opportunistic yeasts (Viollon & Chaumont, 1994) .
For the optical density determination, each plate was shaken for 5 min and the optical density values at 630 nm for each well were read with a microtitre plate reader. For FLC, the susceptibility end point was defined as the lowest concentration of antifungal that resulted in growth reduced by 80 % compared with the control. For THY and AMB, the MIC was defined as the lowest concentration showing 100 % growth suppression.
Chequerboard microdilution assay. Assays were performed on 22 clinical isolates of FLC-resistant C. albicans (Quan et al., 2006) , 12 clinical isolates of FLC-susceptible C. albicans, 2 clinical isolates of C. albicans TW 00313 (CDR1,2 overexpression) and TW 07239 (MDR1/ ERG11 overexpression), 1 experimentally induced FLC-resistant C. albicans S-1 and C. albicans ATCC 10231 as mentioned above, according to the methods of the CLSI (approved standard M27-A) (NCCLS, 1997). The initial concentration of fungal suspension in RPMI 1640 medium was 10 3 c.f.u. ml
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, and the final concentrations ranged from 0.016 to 16 mg ml 21 for AMB, 0.015 to 512 mg ml 21 for FLC and 4 to 512 mg ml 21 for THY. Plates were incubated at 35 uC for 24 h, then a visual reading of the MICs was made, the OD 630 was measured and background optical densities were subtracted from that of each well. Each isolate was tested in triplicate.
In the chequerboard assay, to assess the interaction of combinations of drugs (THY-FLC and THY-AMB), the data obtained by spectrophotometry were further analysed using two non-parametric approaches, fractional inhibitory concentration index (FICI) and DE , which are based on the two major interaction theories Loewe additivity (LA) and Bliss independence (BI), respectively. The LA theory is based on the idea that a drug cannot interact with itself, while the BI theory is based on the idea that two drugs act in ways that are probably independent. In the LA theory the concentrations of the drugs, alone or in combination, that produce the same effect are compared, while in the BI-based models, the estimates of the combined effect based on the effects of the individual drugs were compared with those obtained in the experiment. FICI was defined as the sum of the MIC of each drug when used in combination divided by the MIC of the drug used alone. Synergy and antagonism were defined by FICIs of ¡0.5 and .4, respectively. An FICI result of .0.5 but ¡4 was considered indifferent (Quan et al., 2006) .
, where I i is the predicted percentage of inhibition of the theoretical combination of drugs A and B, and I A and I B are the experimental percentages of inhibition of each drug acting alone. Since I is equal to 1-E, where E is the percentage of growth, by substitution into the former equation, the following equation is derived: E i 5E A 6E B , where E i is the predicted percentage of growth with the theoretical combination of drugs A and B, and E A and E B are the experimental percentages of growth with each drug alone. An interaction is described by the difference DE between the predicted and measured percentages of growth at various concentrations (DE5E predicted 2E measured ). By the non-parametric approach described by Prichard et al. (1993) , E A and E B are obtained directly from the experimental data. Due to the nature of the interaction, testing with microtitre plates and a twofold dilution of either drug results in a DE for each drug combination. In each of the three independent experiments, the observed percentages of growth obtained from the experimental data were subtracted from the predicted percentages, and then the mean difference of three experiments was calculated. When the mean difference and the 95 % confidence interval for the three replicates was positive, a statistically significant synergy was claimed. When the difference and the 95 % confidence interval was negative, significant antagonism was claimed. In any other case, BI was concluded. The values obtained for each combination were depicted on the z-axis used to construct a three-dimensional plot. Peaks above and below the 0 plane indicate synergistic and antagonistic combinations, respectively, whilst the 0 IP: 54.70.40.11
On: Thu, 03 Jan 2019 00:15:10 plane indicates the absence of a statistically significant interaction. As the plot only shows the interactions for each separate combination of the drug concentrations, a value is needed to summarize the interaction surface. This was accomplished by calculating the sum of the percentages of all statistically significant synergistic (gSYN) and antagonistic (gANT) interactions. Interactions with ,100 % statistically significant interactions were considered weak, those with 100-200 % statistically significant interactions were considered moderate, and those with .200 % statistically significant interactions were considered strong . In addition, the numbers of statistically significant synergistic and antagonistic combinations among the 96 combinations of drug concentrations tested were calculated for each strain.
RESULTS AND DISCUSSION

MIC of THY against C. albicans
In this experiment, the MICs of THY against C. albicans strains and ATCC type strains (C. albicans ATCC 10231, C. tropicalis ATCC 13803, C. krusei ATCC 6258 and C. parapsilosis ATCC 90018) were 32-256 mg ml 21 and 64-128 mg ml
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, respectively (Table 1) . These results showed that THY has in vitro antifungal activity against C. albicans. The MICs of FLC against ATCC 6258 and ATCC 90018 were 64 and 0.5 mg ml
, respectively, and both were within the reference ranges. The MICs of AMB against ATCC 6258 and ATCC 90018 were both 1 mg ml
, and both were within the reference ranges.
Drug susceptibility in combination
FICIs of the FLC-THY combination against 34 C. albicans strains ranged from 0.25 to 1, and FICIs of the FLC-THY combination against C. albicans TW 00313, C. albicans TW 07239, C. albicans S-1 and ATCC 10231 were 1.0, 0.5, 0.5 and 0.75, respectively (Table 1) . FICIs of the AMB-THY combination against 34 C. albicans strains ranged from 0.25 to 1.5, and FICIs of the AMB-THY combination against C. albicans TW 00313, C. albicans TW 07239, C. albicans S-1 and ATCC 10231 were 0.5, 0.5, 0.5 and 1, respectively (Table 1) . We did not find antagonistic interactions between FLC-THY or AMB-THY against any strains tested. This result was consistent with another report that the THY oil, and THY as well, exhibit synergism with AMB against C. albicans (Giordani et al., 2004) .
To analyse the interaction of drug combinations (THY-FLC and THY-AMB), we used two non-parametric approaches, FICI and DE, based on the LA and BI interaction theories, respectively. The interaction between FLC and THY against the C. albicans strains is presented in Table 2 . There was good agreement between the FICI and DE methods for the THY-FLC and THY-AMB combinations in all C. albicans strains tested, and we did not find antagonistic interactions between FLC-THY or AMB-THY in these FLC-resistant C. albicans and FLC-susceptible C. albicans.
For all 25 FLC-resistant C. albicans strains tested, the interaction between FLC and THY was synergistic in 24 out of 25 strains by the FICI method, with FICIs ranging from 0.25 to 0.5. By the DE method, 22 out of 25 strains showed a high percentage of synergistic interactions, ranging from 109.8 to 696.5 % ( Table 2 ). The interaction between AMB and THY was synergistic in 22 out of 25 strains by the FICI method, with FICIs ranging from 0.25 to 0.5. By the DE method, 22 out of 25 strains showed a high percentage of synergistic interactions, ranging from 112.8 to 532.5 % (Table 3) .
For 12 clinical isolates of C. albicans susceptible to FLC tested, the interaction between FLC and THY was synergistic in 10 out of 12 strains by the FICI method, with FICIs ranging from 0.25 to 0.5. By the DE method, 9 out of 12 strains showed high percentages of synergistic interactions, ranging from 119.2 to 299.8 % ( Table 2 ). The interaction between AMB and THY was synergistic in 8 out N. Guo and others of 12 strains by the FICI method, with FICIs ranging from 0.25 to 0.5. By the DE method, 9 out of 12 strains showed a high percentage of synergistic interactions, ranging from 106.2 to 302.5 % (Table 3) . By comparison with clinical isolates of C. albicans resistant to FLC, we found that isolates of C. albicans susceptible to FLC were less sensitive to the combination of AMB and THY. While, both the clinical isolates of C. albicans resistant and susceptible to Table 2 . In vitro interaction between THY and FLC For the FICI model, synergy was defined as a FICI of ¡0.5, antagonism was defined as a FICI of .4, and indifference was defined as a FICI of .0.5 to 4 (i.e. no interaction). For the DE model, gSYN and gANT were the sums of the percentages of all statistically significant synergistic and antagonistic interactions. Interactions with ,100 % statistically significant interactions were considered weak synergism, those with 100 to 200 % statistically significant interactions were considered moderate, and those with .200 % statistically significant interactions were considered strong.
Strain
Non-parametric method Antifungal activity of thymol against Candida albicans FLC have the similar sensitivity to the combination of FLC and THY.
Among the models and approaches described for the study of in vitro drug interactions, the LA and BI theories are the two major referenced models (Greco et al., 1995) . The methods used in this study, FICI and DE, are nonparametric models based on the LA and BI theories, respectively. In the FICI model, concentrations of the drugs, alone or in combination, that produce the same effect, are prepared, whereas in the DE model, estimates of the combined effects based on the effects of the individual drugs were compared with those obtained from the experiment. The DE model, developed in recent years, is a useful tool for analysing the nature of interactions between different drugs based on a chequerboard method. When it was used for assessing the interaction between THY-FLC or AMB-THY, the percentages of fungal growth were derived from the experimental data directly, and good agreement was found with the FICI model ; our results also showed good concordance between the FICI and DE models.
From the data above, we can conclude that THY shows potent antifungal effects against clinical C. albicans isolates, including FLC-resistant and FLC-susceptible C. albicans strains, when combined with FLC or AMB, although it shows weak antifungal activity when used alone.
